Pathophysiology and recent therapeutic insights of sickle cell disease

Area of Science:

• Hematology
• Genetics
• Pharmacology

Background:

• Sickle cell disease (SCD) is an inherited blood disorder caused by a mutation in the beta-globin gene.
• Current therapies aim to inhibit SCD's pathological pathways, such as Gardos channel function and cation fluxes, to prevent red blood cell damage and dehydration.
• Pharmacological strategies include using fetal hemoglobin (HbF)-inducing drugs like hydroxyurea to reactivate gamma-globin expression.

Purpose of the Study:

• To review existing and emerging therapeutic strategies for sickle cell disease.
• To discuss the challenges faced by current SCD treatments, particularly in developing countries.
• To explore novel therapeutic avenues, including gene therapy and the potential role of probiotics in modulating hemoglobin.

Main Methods:

• Literature review of established and experimental SCD therapies.
• Analysis of pathophysiological mechanisms underlying SCD.
• Exploration of gene therapy principles for SCD treatment.
• Investigation of emerging approaches like probiotic intervention.

Main Results:

• Various therapies exist, targeting Gardos channels, cation fluxes, and HbF induction.
• Gene therapy presents a promising but complex approach for SCD.
• Significant barriers to treatment access in developing nations include cost and donor availability.
• Probiotics are emerging as a potential novel therapeutic avenue for SCD.

Conclusions:

• Despite advancements, significant challenges remain in SCD treatment accessibility and efficacy.
• Gene therapy offers targeted genetic correction but faces practical hurdles.
• Novel strategies, including the exploration of probiotics, are crucial for developing more effective and accessible SCD therapies.